Bortezomib and rituximab have shown additive activity in preclinical models of lymphoma, and have been shown to be active and generally well tolerated in a randomised phase 2 study in patients with follicular and marginal zone lymphoma. We compared the efficacy and safety of rituximab alone or combined with bortezomib in patients with relapsed or refractory follicular lymphoma in a phase 3 setting.

Coiffier, B., Osmanov, E., Hong, X., Scheliga, A., Mayer, J., Offner, F., et al. (2011). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. THE LANCET ONCOLOGY, 12(8), 773-784 [10.1016/S1470-2045(11)70150-4].

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

CANTONETTI, MARIA;
2011-08-01

Abstract

Bortezomib and rituximab have shown additive activity in preclinical models of lymphoma, and have been shown to be active and generally well tolerated in a randomised phase 2 study in patients with follicular and marginal zone lymphoma. We compared the efficacy and safety of rituximab alone or combined with bortezomib in patients with relapsed or refractory follicular lymphoma in a phase 3 setting.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/15 - Malattie del Sangue
Settore MED/06 - Oncologia Medica
English
Con Impact Factor ISI
Young Adult; Disease-Free Survival; Neoplasm Staging; Antineoplastic Agents; Humans; Lymphoma, Follicular; Aged; Recurrence; Pyrazines; Infusion Pumps; Aged, 80 and over; Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Middle Aged; Female; Male; Antibodies, Monoclonal, Murine-Derived
Coiffier, B., Osmanov, E., Hong, X., Scheliga, A., Mayer, J., Offner, F., et al. (2011). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. THE LANCET ONCOLOGY, 12(8), 773-784 [10.1016/S1470-2045(11)70150-4].
Coiffier, B; Osmanov, E; Hong, X; Scheliga, A; Mayer, J; Offner, F; Rule, S; Teixeira, A; Walewski, J; de Vos, S; Crump, M; Shpilberg, O; Esseltine, D; Zhu, E; Enny, C; Theocharous, P; van de Velde, H; Elsayed, Y; Zinzani, P; Abdulkadyrov, K; Afanasiev, B; Aguayo Gonzalez, A; Andre, M; Belada, D; Ben Yehuda, D; Bezares, R; Biakhov, M; Bolam, S; Borbenyi, Z; Bron, D; Buckstein, R; Bumbea, H; Caballero Barrigon, M; Campos, L; Cantonetti, M; Capra Zanella, M; Christiansen, N; Cohen, G; Colita, N; Cosgriff, T; Crump, M; Culligan, D; Del Giglio, A; Dichmann, R; Dietzfelbinger, H; Digumarti, R; Dmoszynska, A; Domnikova, N; Dubinsky, P; Dunaev, Y; Easow, J; Eberwine, S; Economopoulos, T; Egyed, M; Ellerton, J; Eom, H; Farmer, L; Fenske, T; Fields, P; Fillet, G; Frank, R; Gaisarova, G; Garicochea, B; Gasztonyi, Z; Gavish, I; Gheorghita, E; Gladkov, O; Goldberg, V; Golenkov, A; Gomez Almaguer, D; Gonzalez Barca, E; Guan, Z; Gupta, S; Hellmann, A; Hermann, R; Honkanen, T; Hu, E; Huang, X; Hudecek, J; Illes, A; Intragumtornchai, T; Jedrzejczak, W; Jones, L; Jootar, S; Kahanic, S; Karamanesht, E; Ke, X; Khuageva, N; Kim, W; Kimby, E; Komisarenko, V; Kouroukis, T; Kuliczkowski, K; Kuzina, L; Kyselyova, M; Labanca, V; Lange, A; Le Gouill, S; Leahy, M; Liberati, A; Linden, O; Liu, T; Lubennikov, V; Lundin, J; Lysa, T; Lysenko, I; Lytvyn, I; Makhson, A; Manikhas, G; Masliak, Z; Mcintyre, R; Medvedeva, N; Mena, R; Merkulov, V; Mesters, R; Milpied, N; Min, Y; Moezi, M; Mohrbacher, A; Mollee, P; Morgan, D; Morschhauser, F; Mysanikov, A; Nagler, A; Nair, S; Naparstek, E; Nawarawong, W; Noga, S; Oliveira, I; Okada, C; Oriol Rocafiguera, A; Page, R; Papajik, T; Pasquini, R; Patel, M; Patel, R; Paton, E; Pavlov, V; Pospelova, T; Prasad, S; Pylypenko, H; Raposo, J; Rekhtman, G; Rivas, S; Robak, T; Saba, S; Salles, G; Saltzman, M; Samoilova, O; Samuels, B; Sanani, S; Sebban, C; Silva da Gomes, M; Shen, Z; Shi, Y; Shtalrid, M; Siritanaratkul, N; Skotnicki, A; Solal Celigny, P; Soubeyran, P; Spencer, A; Stevens, D; Suh, C; Sulek, K; Suvorov, A; Szer, J; Theunissen, K; To Bik, L; Tothova, E; Trneny, M; Van De Velde, A; Van Hoof, A; Van Steenweghen, S; Vanhatalo, S; Varma, S; Vidyasagar, M; Vilchevskaya, K; Vitolo, U; Wang, H; Warzocha, K; Wild, A; Zachee, P; Zanichelli, M; Zhang, W; Zoppegno, L; Zoumbos, N
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/69202
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 81
  • ???jsp.display-item.citation.isi??? 74
social impact